Astrazeneca PLC (AZN) closed at $182.27 on November 17, 2026, down 1.0% from the previous close, on volume of 1,936,625 shares (30-day average 2,954,806).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 5, 2026 | Ratio Put Spread 1 by 2 | 18-Dec-26170[2x] : 185 P | 3,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Jefferies Remains a Buy on AstraZeneca (AZN)
TipRanks (Tue, 17-Nov 2:25 PM ET)
Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR
Seeking Alpha News (Tue, 17-Nov 12:22 PM ET)
FDA approves AstraZeneca’s Imfinzi regimen for cisplatin-ineligible MIBC
TipRanks (Mon, 16-Nov 2:36 AM ET)
Klygefa Approved in EU for Adults With Generalised Myasthenia Gravis
TipRanks (Mon, 16-Nov 2:34 AM ET)
Klygefa Approved in US for Adult Anti-AChR-Positive gMG
TipRanks (Mon, 16-Nov 2:33 AM ET)
Baxfendy recommended for EU approval in hypertension
TipRanks (Mon, 16-Nov 2:32 AM ET)
Business Wire (Fri, 13-Nov 6:39 PM ET)
AstraZeneca gains additional bladder cancer indication for Imfinzi
Seeking Alpha News (Fri, 13-Nov 4:23 PM ET)
AstraZeneca eliminates 600 respiratory and immunology sales reps: Bloomberg
Seeking Alpha News (Fri, 13-Nov 2:51 PM ET)
AstraZeneca Updates Benralizumab Asthma Study: What Investors Should Know
TipRanks (Fri, 13-Nov 11:30 AM ET)
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Astrazeneca PLC trades on the NYSE stock market under the symbol AZN.
As of November 17, 2026, AZN stock price declined to $182.27 with 1,936,625 million shares trading.
AZN has a beta of -0.38, meaning it tends to be less sensitive to market movements. AZN has a correlation of 0.00 to the broad based SPY ETF.
AZN has a market cap of $282.57 billion. This is considered a Mega Cap stock.
Last quarter Astrazeneca PLC reported $16 billion in Revenue and $2.79 earnings per share. This beat revenue expectation by $195 million and exceeded earnings estimates by $1.35.
In the last 3 years, AZN traded as high as $212.71 and as low as $60.47.
The top ETF exchange traded funds that AZN belongs to (by Net Assets): PVAL, AVDE, DIHP, DFIC, PPH.
AZN has outperformed the market in the last year with a price return of +114.3% while the SPY ETF gained +10.1%. AZN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +16.5% and -2.3%, respectively, while the SPY returned -5.4% and -2.6%, respectively.
AZN support price is $180.80 and resistance is $187.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZN shares will trade within this expected range on the day.